RT Conference Proceedings
T1 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
A1 Perez Valderrama, B.
A1 Castellano Gauna, D.
A1 Pinto Marin, A.
A1 Mellado Gonzalez, B.
A1 Puente, J.
A1 Climent Duran, M. A.
A1 Domenech, M.
A1 Vazquez Mazon, F. J.
A1 Perez Gracia, J. L.
A1 Bonfill, T.
A1 Morales Barrera, R.
A1 Ballester Navarro, I.
A1 Garcia del Muro, X.
A1 Maroto, P.
A1 Juan Vidal, O. J.
A1 Rodriguez-Vida, A.
A1 Bellmunt, J.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27216
UL https://hdl.handle.net/10668/27216
LA en
DS RISalud
RD Apr 11, 2025